In contrast, the therapeutic potentials of ERβ agonists for the treatment of other pathologies such as prostate cancer or cardiovascular diseases attract researchers to develop selective ERβ agonists as safe and efficacious drugs. Here, ESR2 is linked to prostate carcinoma.